Board of Directors

Oncology Venture is working with a board
of highly skilled individuals

Duncan Moore

Chairman of the board, independent board member

Moore is a board member of Oncology Venture A/S, previously he served as chairman of Oncology Venture Sweden AB (publ) since 2015. Moore is a partner in the company East West Capital Partners and has previously worked as Global Head of Healthcare Research at Morgan Stanley. Duncan has over twenty years experience in capital markets analysis within health care.  

Independent in relation to the Company and its management and the Company’s major shareholders. 

Number of shares: 260 651
Number of warrants: Duncan Moore held 20 000 warrants in Oncology Venture Sweden AB and is entitled to compensation warrants in Oncology Venture A/S.

Frank Knudsen

Deputy Chairman of the board, independent board member

Frank Knudsen has been Chairman of the Board of Directors in Oncology Venture A/S from April 2015- December 2018 and now serves as a deputy Chairman. Frank Knudsen has, along with others, been responsible for life science investments in SEED Capital Denmark K/S and he has also been responsible for the administration and completion of the national finance system for patenting and licensing of research from the universities in Denmark. Presently, Frank Knudsen is director of finance and administration in a private medical practice specializing in gastroenterology.

Independent in relation to the Company and its management and the Company’s major shareholders. 

Number of shares: 8 000.
Number of warrants: 100 000.

Steve Carchedi

CEO of Oncology Venture
Steve Carchedi

Steve is CEO and a Director of Oncology Venture A/S since September 2019 and joined the Board of Directors in October 2019. He brings more than 30 years of commercial industry experience focused in oncology from several leading multinational pharmaceutical biotech companies. Steve has served in CEO positions in both privately owned and Nasdaq listed biotech-companies, all with a late stage oncology focus in which he has led financing, commercialization and re-structuring activities.

He was previously President & Chief Executive Officer of Apexian Pharmaceuticals, an early stage oncology discovery and development company focused in novel targets to treat cancer, and earlier served as Chief Executive Officer of Raphael Pharmaceuticals (formerly Cornerstone Pharmaceuticals), an oncology company focused in cancer metabolism.

Earlier in his career, Steve served as the Senior Vice President and President, Commercial Operations (North America) for Mallinckrodt Pharmaceuticals leading the company listing on NYSE. In addition, he previously held senior leadership positions at General Electric, Johnson & Johnson, Eli Lilly & Company and Bristol Myers Squibb. In addition to his executive experience, Steve currently serves on the Board of Directors of Sunesis Pharmaceuticals and Bionumerik Pharmaceuticals. He previously served on the Board of Directors for Apexian Pharmaceuticals, Cornerstone Pharmaceuticals and PCAsso Diagnostics, LLC, and was Co-Chair of the BioNJ Personalized Medicine & Diagnostics Committee Council (CMOC), the Ontario Institute of Cancer Research Commercial Committee (OICR) and the Pharmaceutical Industry Board of the American Pediatric Family Foundation.

Steve received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University. Steve is a member of the Board of Directors of Sunesis Pharmaceuticals and BioNumerik Pharmaceuticals.

Non-independent director with regard to the Company and its senior management. Independent in relation to the Company’s major shareholders.

Number of warrants: 3 523 875.

 

Steen Knudsen

Chief Science Officer at Oncology Venture

Steen Knudsen is the founder of Oncology Venture A/S and the inventor of DRP®. The Drug Response Prediction Platform is Oncology Venture’s core technology and science platform. Knudsen is a professor emeritus of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. Steen has been a board member since 2004.

Non-independent director with regard to the Company, its senior management and major shareholders.

Number of shares: 6 168 680.
Number of warrants: 0.

Magnus Persson

Independent board member

Dr Persson brings 20 years of international experience from leadership in Life Science innovation, development and financing. He has been a partner in two Life Sciences Venture Capital firms, one with its base in Sweden and with global reach and one in The Bay Area in California. Magnus was previous CEO at Karolinska Institutet Holding AB.

Magnus has extensive experience from medicine, life sciences and biotech financing. He has led development teams on Phase II and III programs in the Pharmaceutical Industry. He has founded, and led private as well as public biotech and medtech companies as Chairman of the Board, Board Director and CEO in the Nordic Countries, Europe and USA.

All in all, he has more than 100 Board years of experience in the life science industry. Magnus has led audit and remuneration committees and several successful recruitment processes for senior management positions. He has a vast international network in the science and biotech financing communities Magnus has been on the board of Oncology Venture since 2014.

Independent in relation to the Company and its management and the Company’s major shareholders.

Number of shares: 0.
Number of warrants: 135 360.

Carani Sanjeevi

Professor, works at Karolinska Institutet, independent board member

Carani Sanjeevi is a board member since 2018. 

Other assignments: Professor and works at Karolinska Institute. Member of the Scientific Advisory Boards of Diamyd Medical and Seraxis.

Previous assignments: Board member of Oncology Venture Sweden AB (publ) and Cadila Pharma Sweden AB. Head of the Molecular Immunogenetics Research Group at Center for Molecular Medicine, Karolinska University Hospital in Stockholm. Received ‘Pravasi Bharathiya Samman Award’ (PBSA) from the President of India in January 2017. The PBSA is the highest honour conferred on overseas Indians or Person of Indian origin by the Government of India in recognition of their achievements both in India and abroad. The Award has been given to Dr. Sanjeevi for, ‘Eminence in one’s field or outstanding work, which has enhanced India’s prestige in the country of residence’.

Independent in relation to the Company and its management and the Company’s major shareholders.

Number of shares: 0.
Number of warrants: 135 360.